• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Mammography World Markets - Product Image

Mammography World Markets

  • Published: December 2012
  • Region: Global
  • 211 Pages
  • TriMark Publications

FEATURED COMPANIES

  • Abviva, Inc.
  • Biosound Esaote, Inc
  • Dexela
  • Hologic, Inc.
  • Philips Healthcare
  • SenoRx, Inc.
  • MORE

Breast cancer is the most common type of cancer in women, affecting one in eight during their lives. Mammography is the most valuable method for detecting potentially cancerous anomalies in the breast. As such, the mammography segment is poised for a major new phase of growth fueled by the availability of new technologies. This TriMark Publications report examines the leading companies engaged in marketing, manufacturing or developing mammography equipment and supplies in the world. Each company is discussed in extensive depth with a section on its product line, business and marketing analysis, and a subjective commentary of the company’s market position. Detailed tables and charts with sales forecasts and market share data are also included.

Mammograms are X-ray images of the breast produced from low radiation X-rays (1-3 milligrays, or mGy).

The three types of mammography systems are:
1) analog systems,
2) computed tomography (CR) systems and
3) full-field digital mammography (FFDM).

The analog systems are the conventional types, and they use X-ray films for capturing the breast images. The CR systems are also film-based, but are retrofitted with READ MORE >

1. Overview
1.1 Statement of Report
1.2 Scope of this Report
1.3 Methodology
1.4 Executive Summary

2. Technology Trends in Mammography
2.1 Rationale for Digital Mammography
2.1.1 The Technology
2.1.1.2 Mammography Reading
2.2 Research Studies
2.3 Contrast Injection Mammography
2.4 Digital Breast Tomosynthesis (DBT)
2.5 Dedicated CT of the Breast

3. Mammography Overview
3.1 Early Mammography
3.2 The First Digital Mammography System
3.3 Mammography Technique and Types
3.3.1 Screening Mammogram
3.3.1.1 Cost of Screening Mammogram in the U.S.
3.3.1.2 Interpretation of Mammogram
3.4 Signs and Symptoms of Breast Cancer
3.4.1 Need for MRI
3.5 Most Common Breast Conditions Seen in Screening Mammography
3.5.1 Fibroadenoma
3.5.2 Galactocele
3.5.4 Adenosis
3.5.5 Phyllodes Tumor
3.5.6 Infiltrating Duct Carcinoma
3.5.7 Duct Carcinoma in situ
3.6 Diagnostic Mammography
3.6.1 Views with Diagnostic Mammography
3.6.2 Anomalies Detected by Diagnostic Mammography
3.7 Other exams to Evaluate Breast Anomaly
3.7.1 Computer-Aided Detection in Breast Imaging
3.7.2 Ductal Lavage
3.7.3 Scintimammography
3.7.4 Positron Emission Tomography (PET) in Breast Imaging
3.8 Staging and Survival Rates of Breast Cancer
3.8.1 Numerical Stages of Breast Cancer
3.9 Breast Cancer Stages and Survival Rate
3.9.1 Histologic Grading of Breast Cancer
3.10 Hormone Receptor Status in Breast Cancer
3.11 Metastatic Breast Cancer (MBC)
3.12 Breast Cancer Treatments
3.12.1 Breast Cancer Surgery
3.12.1.1 Breast Conserving Surgery
3.12.1.2 Total Mastectomy
3.12.1.3 Modified Radical Mastectomy
3.12.2 Radiation Therapy
3.12.2.1 External Radiation Therapy
3.12.2.2 Internal Radiation Therapy
3.12.3 Hormone Therapy
3.12.4 Targeted Therapy
3.12.5 Chemotherapy
3.12.5.1 Classes of Breast Cancer Drugs
3.12.5.1.1 Selective Estrogen-Receptor Modulators (SERMs)
3.12.5.1.2 Aromatase Inhibitors
3.12.5.1.3 Biologic Response Modifiers
3.12.6 Profiles of Breast Cancer Drugs
3.12.6.1 Abraxane (paclitaxel protein-bound particles for injectable suspension)
3.12.6.2 Adriamycin (doxorubicin)
3.12.6.3 Aredia (pamidronate disodium)
3.12.6.4 Arimidex (anastrozole)
3.12.6.5 Aromasin (exemestane)
3.12.6.6 Chemotherapy Regimens
3.12.6.7 Cytoxan (cyclophosphamide)
3.12.6.8 Ellence (epirubicin)
3.12.6.9 Evista (raloxifene)
3.12.6.10 Fareston (toremifene)
3.12.6.11 Femara (letrozole)
3.12.6.12 Herceptin (trastuzumab)
3.12.6.13 Megace (megestrol)
3.12.6.14 Tamoxifen
3.12.6.15 Taxol (paclitaxel)
3.12.6.16 Taxotere (docetaxel)
3.12.6.17 Xeloda (capecitabine)
3.12.6.18 Zoladex (goserelin acetate)
3.12.6.19 Zometa (zoledronic acid)
3.13 Breast Reconstruction after Breast Cancer Surgery and Radiation Therapy
3.13.1 Delayed Reconstruction and Radiation
3.13.2 Reconstructing the Irradiated Lumpectomy Breast Deformity
3.13.3 Genetic Testing and Prophylactic Mastectomy
3.14 Types of Mastectomy
3.14.1 Skin-Sparing Mastectomy
3.14.2 Nipple-Sparing Mastectomy
3.14.3 Areola-Sparing Mastectomy
3.14.4 Skin-Reducing Mastectomy
3.14.5 Expander Implant Post Mastectomy Reconstruction
3.14.6 Direct Implant ("One-Step") Breast Reconstruction
3.14.7 Latissimus Dorsi Flap
3.14.8 TRAM Flap Reconstruction
3.14.9 TUG Flap - Inner Thigh Flap Breast Reconstruction
3.14.10 GAP Flap, Other Free Flaps
3.14.11 Implants Used in Breast Reconstruction
3.14.11.1 Types of Breast Implants
3.15 Known Risk Factors for Breast Cancer
3.15.1 Increasing Age
3.15.2 Family History of Breast Cancer and Genetic Predisposition
3.15.3 Hormonal Factors
3.15.4 Clinical Factors
3.15.5 Radiation
3.16 Prevention of Breast Cancer
3.16.1 Obesity
3.16.2 Alcohol Consumption
3.16.3 Tobacco
3.16.4 Menopausal Hormones

4. Breast Cancer and Mammography Data
4.1 Global Breast Cancer Incidence and Mortality
4.2 Characteristics of Breast Cancer Cases
4.3 U.S. Data on Breast Cancer and Mammography
4.3.1 New Breast Cancer Incidence in the U.S.
4.3.2.1 Breast Cancer and Mammography in White Women
4.3.2.2 Breast Cancer and Mammography in Hispanic Women
4.3.2.3 Breast Cancer and Mammography in African-Americans
4.3.2.4 Breast Cancer and Mammography in Asian Pacific Islanders
4.3.2.5 Breast Cancer and Mammography in Native Americans
4.3.2.6 Breast Cancer and Mammography in Ashkenazi Jews
4.3.3 Educational Level and Breast Cancer Incidence in the U.S.
4.3.4 Mammography Percentages by Age in the U.S.
4.3.5 Financial Impact of Breast Reconstruction
4.3.5.1 Payment and Reimbursement Guidelines in 2008 for Intraoperative Electron Radiation Therapy (IOERT)
4.3.5.2 Medicare Inpatient Hospital Payment
4.3.5.3 Rise in Payments for Breast Cancer in the U.S.
4.3.6 Research Funding for Cancer Research in the U.S.
4.3.6.1 NIH Funding Mechanisms
4.3.6.2 Percent Share of Total NCI Dollars
4.3.6.3 Actual Obligations by Mechanism
4.3.7 Funding Trends
4.3.7.1 Research Project Grants
4.3.7.2 Research Career Awards - "K" Program
4.3.7.3 NCI Funding by Cancer Type
4.3.7.4 Funding for Breast Cancer Research
4.3.7.5 Research Areas in Breast Cancer
4.3.7.6 NCI-Designated Cancer Centers
4.3.7.7 NCI's Funding by State
4.3.7.8 2011 Professional Judgment Budget Request
4.4 Breast Cancer Screening in E.U.
4.4.1 Number of People Affected by Screening in E.U.
4.4.2 Program Implementation Status in E.U.
4.4.3 Variation between Member States in E.U.
4.4.4 Breast Cancer Incidence and Mortality in the U.K.
4.4.4.1 Socio-Economic Variations
4.4.4.2 Breast Cancer Trends in U.K.
4.4.4.3 Breast Cancer Incidence in U.K.
4.4.4.4 Mastectomy and Breast Reconstruction Surgery in U.K.
4.4.4.5 Outcomes of Mastectomy and Reconstruction
4.4.4.6 Patient Characteristics and Patterns of Care
4.4.4.7 Types of Primary Breast Reconstruction in U.K.
4.4.4.8 Types of Contralateral and Secondary Reconstructive Procedures
4.4.4.9 National-Level Inpatient Complication Rates
4.4.4.10 Breast Cancer Research in U.K.
4.4.4.11 Breast Screening Programs in England as of 2009
4.4.5 Breast Cancer Screening in Australia
4.4.5.1 Breast Cancer Projections in Australia
4.4.5.2 Trends in Medicare Benefits Schedule (MBS) Funded Mammography
4.4.5.3 Analysis of MBS Funded Mammography by Age
4.4.5.4 MBS Funded Diagnostic Services for Breast Cancer

5. Market Analysis
5.1 Points to be considered Before Buying a Mammography System
5.1.1 Cost Containment in Mammography Systems
5.2 Global Market for Mammography
5.2 Global Market for Film-Based Mammography Systems
5.3 Global Market for Digital Mammography
5.4 Global Breast Cancer Drugs Market
5.5 Global Cancer Biomarkers Market
5.6 Leading Players in Global Cancer Pharmaceuticals
5.7 Global Spending on Cancer Drugs
5.8 Mammogram Procedure Growth in the U.S.
5.8.1 Approved Mammography Facilities in the U.S.
5.8.2 Mammography Quality Standards Act (MQSA) National Statistics
5.8.3 Decline in the Number of Mammography Facilities in the U.S.
5.8.4 Number of Mammography Units in the U.S.
5.8.5 U.S. Mammography Equipment Market
5.8.6 Digital Mammography: Market Penetration in the U.S.
5.9 Business Plan for Digital Mammography
5.10 Breast Cancer and Genetic Testing in the U.S.
5.11 U.S. Market for Brachytherapy Products
5.12 U.S. Market for Breast Irradiation
5.13 Reimbursement for Mammography Procedures
5.14 Global Market for Breast Cancer Drugs
5.14.1 Avastin
5.14.2 Herceptin
5.14.3 Xeloda
5.15 Global Market for Cancer Therapies
5.16 Global Market for Biological Therapies in Cancer
5.16.2 U.S. Market for Biological Therapies in Cancer
5.16.3 European Market for Biological Cancer Therapies
5.16.4 Market for Biological Cancer Therapies in Japan
5.16.6 Market for Biological Cancer Therapies in Rest of the World
5.17 Market for Other Imaging Modalities
5.17.1 Popular Medical Imaging Systems
5.18 Global Market for Medical Imaging
5.18.1 Global Medical Imaging Market by Modality
5.18.2 Global Market for General X-rays
5.18.3 Global Market for Ultrasound (US)
5.18.4 Global Market for Portable Ultrasound
5.18.5 Global Market for Magnetic Resonance Imaging
5.18.6 Global Market for Computed Tomography
5.18.7 Global Market for Nuclear Medicine
5.18.8 Global Market for SPECT/PET
5.18.9 Global Market for PET/CT
5.18.10 Global Medical Displays and Post-Processing Software Market
5.19 North American Market for Medical Imaging
5.19.1 North American Market for Magnetic Resonance Imaging (MRI)
5.19.2 U.S. Market for Computed Tomography
5.19.3 U.S. Market for Multi-Slice CT Scanners
5.19.4 U.S. Market for SPECT and PET Radiopharmaceuticals
5.19.5 U.S. Market for SPECT
5.19.6 U.S. Market for Positron Emission Tomography (PET)
5.19.7 Medical Imaging in Canada
5.20 Medical Imaging Market in Europe
5.20.1 Medical Imaging Market in Central Europe
5.20.2 European Market for Digital Radiography (DR)
5.20.3 European Market for Computed Radiography
5.20.4 European Market for MRI
5.20.5 European Market for Digital Radiography (DR)
5.20.6 European Market for Computed Radiography (CR)
5.21 Emerging Markets in Medical Imaging
5.21.1 Medical Imaging in China and India
5.21.2 Medical Imaging Market in China
5.21.3 Market for Ultrasound in China
5.21.4 Medical Imaging Market in India

6. Company Profiles
6.1 Abviva, Inc.
6.1.1 Mammastatin Serum Assay (MSA)
6.2 Agendia B.V.
6.2.1 MammaPrint
6.2.2 BluePrint
6.2.3 TargetPrint
6.3 Agfa Healthcare
6.4 Amgen, Inc.
6.4.1 Amgen's Cancer Drugs
6.4.1.1 Aranesp (darbepoetin alfa)
6.4.1.2 Xgeva (denosumab)
6.4.1.3 Vectibix (panitumumab)
6.4.1.4 Neulasta (pegfilgrastim)
6.5 Analogic Corporation
6.5.1 Analogic's CT Systems and Subsystems
6.5.2 Analogic's MRI Power Solutions
6.5.3 Analogic's Specialized Ultrasound Solutions
6.5.4 Analogic's Digital Radiography Subsystems
6.5.5 Analogic's Radiation Therapy Solutions
6.6 Ardent Sound, Inc
6.7 AstraZeneca
6.7.1 Arimidex
6.7.2 Faslodex
6.7.3 Casodex
6.7.4 Zoladex
6.7.5 Iressa
6.8 Aurora Imaging Technology, Inc.
6.8.1 Aurora 1.5T Dedicated Breast MRI System
6.9 C.R. Bard, Inc.
6.10 Biosound Esaote, Inc
6.11 Bristol-Myers Squibb
6.11.1 Ixempra (ixabepilone)
6.11.2 Erbitux (cetuximab)
6.11.3 Sprycel (dasatinib)
6.12 Canon U.S.A., Inc
6.13 Chison Medical Imaging, Co., Ltd
6.14 Clarient, Inc.
6.15 Dako
6.15.1 Dako's Products
6.16 deCODE Genetics
6.16.1 deCODE BreastCancer
6.17 Dilon Technologies, Inc.
6.17.1 Dilon 6800 Gamma Camera
6.17.2 The GammaLoc System
6.17.3 PenRad Mammography Information System
6.18 Dexela
6.18.1 Dexela Digital Mammography Workstation
6.19 Eli Lilly
6.19.1 Eli Lilly's Oncology Products
6.20 Encapsule Medical Devices, LLC.
6.21 Fonar Corporation
6.21.1 Fonar's Upright MRI
6.21.2 Fonar 3600
6.22 Fujifilm Medical Systems USA, Inc.
6.23 Fukuda Denshi Co., Ltd.
6.24 GE Healthcare
6.25 Genentech, Inc.
6.25.1 Genentech's Oncology Products
6.25.1.1 Avastin (bevacizumab)
6.25.1.2 Herceptin (Trastuzumab)
6.25.1.3 Rituxan
6.25.1.4 Tarceva (erlotinib)
6.25.1.5 Xeloda (capecitabine)
6.26 Hitachi Medical Corporation
6.27 Hologic, Inc.
6.27.1 Hologic's Breast Health Products
6.27.1.1 Selenia Full Field Digital Mammography System
6.27.1.2 Breast Tomosynthesis
6.27.1.3 Screen-Film Mammography Systems
6.27.1.4 SecurView Workstation
6.27.1.5 CAD Systems
6.27.1.6 Stereotactic Breast Biopsy Systems
6.27.1.7 Breast Biopsy Products
6.27.1.8 Breast Brachytherapy Products
6.27.1.9 MammoPad Breast Cushion
6.27.1.10 Photoconductor Coatings
6.27.1.11 Sentinelle Medical MRI Breast Coils and Workstation
6.28 Imaging Diagnostic Systems, Inc.
6.28.1 Computed Tomography Laser Mammography (CTLM)
6.29 Konica Minolta Medical Imaging USA, Inc.
6.29.1 Xpress CR
6.29.2 REGIUS PureView System
6.30 MacKay LifeSciences
6.30.1 Breast Cancer Diagnostic System (BDS)
6.31 Lantheus Medical Imaging, Inc.
6.32 Medis Medical Imaging Systems BV
6.33 Medical Tactile, Inc
6.33.1 SureTouch System
6.34 Medison America, Inc.
6.35 Medtronic Navigation and Imaging
6.35.1 PoleStar Surgical MRI system
6.35.2 StealthStation i7
6.35.3 O-arm Surgical Imaging System
6.35.4 StealthViz Advanced Visualization and Planning
6.36 MeVis Medical Solutions AG
6.36.1 MeVis Software for Digital Mammography
6.36.2 Syngo MammoReport
6.36.3 SecurView DX
6.36.4 DynaCAD
6.37 Naviscan PET Systems, Inc.
6.37.1 Naviscan PEM Scanner
6.38 NeoMatrix LLC
6.38.1 HALO Breast Pap Test
6.39 Novartis AG
6.39.1 Femara
6.39.1.1 The Action of Femara
6.40 Philips Healthcare
6.40.1 Philips PCR Eleva CosimaX system
6.40.2 Integral Breast Workspace solution from Philips Healthcare
6.40.3 Breast Ultrasound from Philips Healthcare
6.40.4 MammoDiagnost
6.40.5 MammoDiagnost DR
6.40.6 MammoDiagnost with PCR Eleva
6.41 Pfizer, Inc.
6.41.1 Pfizer's Pipeline of Therapeutics
6.42 Roche Holdings, Ltd.
6.42.1 Roche's Cancer Pharmaceuticals
6.42.2 Avastin
6.42.3 MabThera/Rituxan
6.42.4 Herceptin (trastuzumab)
6.42.5 Xeloda (capecitabine)
6.42.6 Tarceva (erlotinib)
6.42.7 Regulatory Approvals for Roche's Cancer Drugs
6.43 Sanarus Technologies, LLC
6.43.1 Sanarus Visica cryoablation treatment system
6.44 Sanofi-Aventis
6.44.1 Taxotere
6.44.2 Eloxatine (oxaliplatin)
6.44.3 Sanofi's Oncology Pipeline
6.45 Sectra Medical Systems
6.45.1 Sectra MicroDose Mammography
6.45.2 Sectra Breast Imaging RIS/PACS
6.46 Planmed
6.47 Scanis, Inc.
6.47.1 Mammex MammoCAD System
6.48 Siemens Healthcare
6.48.1 Digital Mammography from Siemens
6.48.2 3D Breast Tomosynthesis
6.48.3 Mammomat Novation
6.49 SenoRx, Inc.
6.49.1 EnCor Breast Biopsy System
6.49.2 SenoRx Family of Markers
6.49.3 Contura Multi-Lumen Balloon (MLB)
6.49.4 Gamma Finder
6.50 Shimadzu Medical Systems
6.51 SonoCine, Inc.
6.51.1 SonoCine
6.52 TechniScan Medical Systems
6.52.1 Svara Warm Bath Ultrasound (WBU)
6.53 Toshiba America Medical Systems, Inc.
6.53.1 Infinix-i systems
6.53.2 Aquilion ONE CT System
6.53.3 Vantage Titan
6.53.4 Viamo
6.53.5 Radrex-i
6.54 U-Systems, Inc.
6.54.1 SomoV Automated 3D Breast Ultrasound System
6.55 Varian Medical Systems
6.55.1 Varian's Oncology Business
6.55.2 Varian's X-Ray Business
6.56 VuCOMP, Inc.
6.56.1 M-Vu CAD system
6.56.2 M-Vu Digital CAD system
6.56.3 M-Vu Viewer Station
6.56.4 M-Vu Digitize + Archive

APPENDIX

Appendix 1: Breast Cancer Nutrition
Appendix 1.1: Vegetables and Fruits
Appendix 1.2: Grains
Appendix 1.3: Meat and Fish
Appendix 1.4: Alcohol and Beverages
Appendix 2: Breast Cancer Statistics
Appendix 3: Integration of Digital Mammography on PACS
Appendix 3.1: Considerations in Deploying Digital Mammography
Appendix 4: CAD for Digital Mammography Using Syngo MammoCAD
Appendix 5: BRIDGE Metastatic Breast Survey
Appendix 5.1: BRIDGE Metastatic Breast Cancer (MBC) Survey
Appendix 5.2: Psychological Impact of Breast Cancer
Appendix 5.3: Preast Cancer Patients' Outlook on Life
Appendix 5.4: Role of Information in Helping Women to Cope with MBC
Appendix 5.5: Clinical Trial Awareness and Experience in MBC
Appendix 5.6: Reasons for Not Participating in Clinical Trial
Appendix 5.7: The Role of Information and "Inforemation Seeking Women"
Appendix 6: Clinical Trials in Mammography as of December 2010
Appendix 7: Advances against Cancer in the Past 150 years
Appendix 8: Emerging Technologies in Breast Cancer Detection
Appendix 8.1: Digital Mammography
Appendix 8.2: Indirect-Conversion Digital Detectors
Appendix 8.3: Direct-Conversion Digital Detectors
Appendix 8.4: Contrast-Enhanced Mammography
Appendix 8.5: Breast Tomosynthesis
Appendix 8.6: Digital Mammography/Ultrasound Fusion
Appendix 8.7: Computer-Aided Detection
Appendix 8.8: Magnetic Resonance Imaging (MRI)
Appendix 8.9: Breast Ultrasound
Appendix 8.10: Breast Thermography
Appendix 8.11: Positron Emission Tomography (PET)
Appendix 8.12: Scintimammography
Appendix 8.13: Near Infrared Optical Imaging
Appendix 8.14: Bioelectric Imaging
Appendix 9: Medical Imaging Technologies
Appendix 9.1: Ultrasound Systems
Appendix 9.2: Computed Tomography (CT)
Appendix 9.3: Magnetic Resonance Imaging (MRI)
Appendix 9.4: Digital X-Ray
Appendix 9.5: Positron Emission Tomography (PET)
Appendix 10: The Supply of Medical Radioisotopes
Appendix 10.1: Potential for New Reactors
Appendix 10.2: Processing Capacities and Restraints
Appendix 11: Opportunities in the Middle East for Healthcare and Medical Imaging
Appendix 11.1: The largest U.S. Customers in the Middle East Region
Appendix 11.2: U.S. Exports of Medical Imaging Products to the Middle East, 2009
Appendix 12: Value of Radiation Therapy and Medical Imaging
Appendix 12.1: Effective Use of Medical Radiation
Appendix 12.2: Innovations to Reduce Radiation Dose
Appendix 12.3: Innovation in CT Imaging
Appendix 12.4: Effectiveness of Radiation Therapy
Appendix 12.5: Efforts to Minimize Radiation Dose
Appendix 12.6: New Dose-Check Features
Appendix 13: Health and Medical Imaging Expenditures in OECD Countries
Appendix 13.1: Medical Imaging Equipment and Utilization Statistics
Appendix 13.2: CT Scanners per Million
Appendix 13.3: Gamma Cameras per Million of Population in OECD Countries
Appendix 13.4: Mammography Units per Million of Population in OECD Countries
Appendix 13.5: MRI Scanners per Million Population in OECD Countries
Appendix 13.6: PET Scanners per Million of Population in OECD Countries
Appendix 13.7: Utilization of Medical Imaging Modalities in OECD Countries
Appendix 13.8: CT Exams per 1,000 of Population in OECD Countries
Appendix 13.9: MRI Exams per Scanner in OECD Countries
Appendix 13.10: MRI Exams per 1,000 of Population in OECD Countries

INDEX OF FIGURES

Figure 1.1: Growth of Digital Mammography in the U.S., 2003-2008
Figure 1.2: Digital Mammography System that Uses a Direct Conversion Flat-Panel Detector
Figure 1.3: Digital Mammography Plate Reading Station
Figure 1.4: A Digital Mammography Workstation
Figure 1.5: Tomosynthesis Scanner from GE
Figure 1.6: Standard 2D and Tomosynthesis Slice Breast Images
Figure 3.1: Attention Given to MBC Compared with EBC in Different Countries, 2008
Figure 3.2: Patients' Emotions When Given a Diagnosis of Metastatic Breast Cancer (MBC)
Figure 3.3: Patients' Concerns when Given a Diagnosis of Metastatic Breast cancer (MBC)
Figure 4.1: Percent Incidence of Sporadic and Familial Breast Cancer
Figure 4.2: Global Breast Cancer Incidence and Mortality in Select Regions as of 2008
Figure 4.3: Number of Women Diagnosed with Breast Cancer by Age and Type of Disease, 1996-2008
Figure 4.4: Number of Women Diagnosed with Breast Cancer by Year and Type of Disease, 1996-2008
Figure 4.5: Distribution of Number of Screening Mammograms per Woman for 1996-2008
Figure 4.6: Distribution of U.S. Women in 2008 by Race/Ethnicity
Figure 4.7: New Breast Cancer Incidence in North America, 2009-2017
Figure 4.8: Percent of White Women in the U.S. Opted for Mammogram, 2000-2008
Figure 4.9: Percent Hispanic or Latina Women in the U.S. Opted for mammogram, 2000-2008
Figure 4.10: Percent of African-American Women in the U.S. Opted for Mammograms, 2000-2008
Figure 4.11: Percent of Asian Women in the U.S. Opted for Mammograms, 2000-2008
Figure 4.12: Percent of Native American Women Opted for Mammograms, 2000-2008
Figure 4.13: Percentage of U.S. Women Aged 40 Years and Older Who Have Had a Mammogram by Race and Ethnicity, 2000-2008
Figure 4.14: Percentage of U.S. Women Aged 40 Years and Older Who Have Had a Mammogram by Education Level, 2000-2008
Figure 4.15: Percentage of U.S. Women Aged 40 Years and Older Who Have Had a Mammogram by Age, 2000-2008
Figure 4.16: Physician Reimbursement for Unilateral Breast Reconstruction by Operating Room Time Utilization
Figure 4.17: Blue Cross/Blue Shield Physician Reimbursement for Unilateral Breast Reconstruction
Figure 4.18: Total Cost per Episode in the U.S., 2003-2007
Figure 4.19: National Cancer Institute 2009 Actual Obligations by Mechanism ($4.967 Millions)
Figure 4.20: National Cancer Institute % Share of Total RPG Funds, 2009
Figure 4.21: Research Dollars Allocated by NCI for Breast Cancer, 2005-2009
Figure 4.22: NCI Breast Cancer Research Portfolio: Percentage of Total Dollars by Scientific Area, 2008
Figure 4.23: Type and Status of Breast Cancer Screening Programs in E.U. Member States in 2007
Figure 4.24: Type and Status of Breast Cancer Screening Programs in Women aged 50 to 69 in the E.U. Member States in 2007
Figure 4.25: Incidence and Mortality Rates in Six of the E.U. 27 Countries, 2008
Figure 4.26: Breast Cancer Incidence and Mortality Rates in U.K., 1975-2007
Figure 4.27: Age Specific Breast Cancer Incidence Rates in the U.K., 1975-2007
Figure 4.28: Age-Specific Incidence Rate of Breast Cancer in U.K., 2007
Figure 4.29: Percentage coverage for women aged 53-70, 53-64 and 65-70, England 2006-2009
Figure 4.30: Incidence of Breast Cancer in Australia: Projections from 2007 to 2015
Figure 4.31: Annual Numbers of Mammograms, Both Breasts and One Breast, Women 50-69 years, 1987-2007
Figure 4.32: Age-Specific Rate of Mammograms, Both Breasts, by Age Group, 2006 and 2007
Figure 4.33: Age-Specific Rate of Mammograms, Both Breasts by Age Group, 2007
Figure 4.34: Age-Specific Rate of mammograms, one breast (MBS item 59303) by age group, 2007
Figure 5.1: Global Market for Mammography, 2010-2016
Figure 5.2: Global Market for Film-Based Mammography Systems, 2010-2016
Figure 5.3: Global Market for Digital Mammography Equipment, 2010-2016
Figure 5.4: Global Market for Breast Cancer Drugs, 2010-2016
Figure 5.5: Global Market for Biomarkers, 2010-2016
Figure 5.6: Biomarker Patent Filings by Type of Cancer, 2010
Figure 5.7: Top Ten Companies in Global Cancer Therapeutics Market, 2009
Figure 5.8: Projected Sales of Avastin, 2008-2015
Figure 5.9: Top Ten Therapies in Global Cancer Therapeutics Market, 2008
Figure 5.10: Oncology Drug Spending in Major European Countries, 2009
Figure 5.11: U.S. Mammogram Procedure Growth, 2010-2016
Figure 5.12: Number of Certified Mammography Facilities, 2000-2010
Figure 5.13: Number of Mammography Units in the U.S., 2000-2010
Figure 5.14: U.S. Mammography Equipment market, 2009-2016
Figure 5.15: U.S. Market for Breast Cancer Genetic Testing, 2010-2016
Figure 5.16: U.S. Market for Brachytherapy Products, 2010-2016
Figure 5.17: U.S. Market for Partial Breast Irradiation, 2008-2016
Figure 5.18: Avastin: HER2-negative metastatic Breast Cancer (mBC) 2010 Population
Figure 5.19: Herceptin: HER2+ Early Breast Cancer (eBC) 2010 Population
Figure 5.20: Herceptin: HER2+ Metastatic Breast Cancer (mBC) 2010 Population
Figure 5.21: Xeloda: Adjuvant Breast Cancer (eBC) 2010 Population
Figure 5.22: Xeloda: Metastatic Breast Cancer (mBC) 2010 Population
Figure 5.23: Global Cancer Market by Therapy Area, 2009
Figure 5.24: Global Market for Biological Therapies in Cancer, 2009-2014
Figure 5.25: U.S. Market for Biological Cancer Therapies, 2009-2014
Figure 5.26: Europe/ROW market for Biological Cancer Therapies, 2009-2014
Figure 5.27: Japanese Market for Biological Cancer Therapies, 2009-2014
Figure 5.28: Market for Biological Cancer Therapies in Rest of the World, 2009-2014
Figure 5.29: Global Medical Imaging Market (%) by Region, 2009
Figure 5.30: Global Medical Imaging Market (%) by Modality, 2009
Figure 5.31: Global Market for General X-rays, 2010-2016
Figure 5.32: Global Market for Ultrasound, 2010-2016
Figure 5.33: Global Market for Portable Ultrasound Equipment, 2009-2014
Figure 5.34: Global Percent MRI Market by Geography, 2010
Figure 5.35: Global Market for MRI, 2010-2016
Figure 5.36: Global Market for CT, 2004-2009
Figure 5.37: Global Market for Computed Tomography, 2010-2016
Figure 5.38: Global Market for Nuclear Medicine, 2010-2016
Figure 5.39: Global Market for SPECT/PET, 2010-2015
Figure 5.40: Global Market for PET/CT, 2010-2015
Figure 5.41: Global Market for Medical Displays and Post-Processing Software, 2009-2014
Figure 5.42: North American Market for Medical Imaging Equipment, 2010-2016
Figure 5.43: North American Market for MRI, 2010-2015
Figure 5.44: U.S. Market for Computed Tomography, 2010-2016
Figure 5.45: Market for Multi-Slice CT Scanners in the U.S., 2010-2016
Figure 5.46: U.S. Market for Radiopharmaceuticals, 2009-2017
Figure 5.47: U.S. Market for SPECT, 2009-2017
Figure 5.48: U.S. Market for PET, 2009-2017
Figure 5.49: Market for Medical Imaging Modalities in Canada, 2009-2014
Figure 5.50: Percent Distribution of Diagnostic Imaging Examinations in Canadian Hospitals
Figure 5.51: Western European Market for Medical Imaging, 2009-2016
Figure 5.52: Imaging Diagnostics Market in Central Europe, 2009-2012
Figure 5.53: European Market for Digital Radiography, 2009-2016
Figure 5.54: European Market for Computed Radiography, 2009-2016
Figure 5.55: European Market for MRI, 2010-2015
Figure 5.56: European Market for Digital Radiography (DR), 2009-2016
Figure 5.57: European Market for Computed Radiography, 2009-2016
Figure 5.58: Medical Imaging in Emerging Markets, 2010-2016
Figure 5.59: Market for Medical Imaging Equipment in Greater China, 2010-2016
Figure 5.60: Market for Ultrasound Equipment in China, 2009-2014
Figure 5.61: Medical Imaging Market in India, 2010-2016
Figure 6.1: Performance of Eli Lilly's Cancer Drugs by Geography, 2009
Figure 6.2: Eleva User Interface
Figure 6.3: Roche's Performance in Pharmaceuticals in the first Six Months of 2010
Figure 6.4: Volume Growth in Net Orders for Varian's Oncology Systems, 2007-2009
Figure 6.5: Volume Growth in Net Orders for Varian's X-Ray Products, 2007-2009
Figure App. 3.1: Workflow using Philips' iSite Radiology for mammography SCR
Figure App. 3.2: Workflow using third party workstation for mammography SCR
Figure App. 4.1: Digital Workflow with CAD
Figure App. 5.1: Public Attention Given to MBC
Figure App. 5.2: Women Afraid to Talk Openly About their Experiences with MBC
Figure App. 5.3: MBC Patient's Outlook on life
Figure App. 5.4: Women with MBC Who Have Participated in a Clinical Trial
Figure App. 5.5: Reasons for Not Participating in a Clinical Trial
Figure App. 5.6: Respondents who have looked for Information on Clinical Trials
Figure App. 9.1: Block Diagram of Imaging Ultrasound Equipment
Figure App. 9.2: Block Diagram of Medical CT System
Figure App. 9.3: Block Diagram of Medical MRI
Figure App. 9.4: Block Diagram of Digital X-Ray
Figure App. 9.5: Block Diagram of PET
Figure App. 10.1: Current Supply and Demand for Medical Radioisotopes, 2010-2024
Figure App. 10.2: Percent Market Share of Medical Radioisotopes by Reactor, 2010
Figure App. 11.1: U.S. Exports of Medical Products to the Middle East, 1996-2009
Figure App. 11.2: U.S. Exports of Medical Products to Israel, Saudi Arabia and Turkey, 2009
Figure App. 11.3: U.S. Exports of Medical Imaging Products to Israel, Saudi Arabia and Turkey, 1996-2009
Figure App. 13.1: Public and Private Expenditure on Health % of GDP in Select OECD Countries
Figure App. 13.2: Angiography Units per Million of Population in OECD Countries
Figure App. 13.3: CT Scanners per Million of Population in OECD Countries
Figure App. 13.4: Gamma Cameras per Million of Population in OECD Countries
Figure App. 13.5: Mammography Units per Million of Population in OECD Countries
Figure App. 13.6: MRI Scanners per Million of Population in OECD Countries
Figure App. 13.7: PET Scanners per Million of Population in OECD Countries
Figure App. 13.8: CT Exams per Scanner in OECD Countries
Figure App. 13.9: CT Exams per 1,000 of Population in OECD Countries
Figure App. 13.10: MRI Exams per Scanner in OECD Countries
Figure App. 13.11: MRI Exams per 1,000 of Population in OECD Countries

INDEX OF TABLES

Table 3.1: Percent of American Women Who Had Mammograms in the Past Two years
Table 3.2: Size of Tumors Found by Mammography and Breast Self-Examination
Table 3.3: BI-RADS Assessment Categories
Table 3.4: Screening Guidelines for the Early Detection of Breast Cancer in Average-risk, Asymptomatic Women Aged 20 Years and Older
Table 3.5: Pros and Cons of Ultrasound and MRI in Breast Imaging
Table 3.6: Staging of Breast Cancer
Table 3.7: Breast Cancer Survival Rate by Stage
Table 3.8: Histologic Grade System for Breast Cancer
Table 3.9: Breast Cancer Grades and Description
Table 3.10: Activities and Materials Women with MBC value
Table 3.11: Classes of Tests Used to Treat Breast Cancer
Table 3.12: Silicone vs. Silicone Implants
Table 3.13: Factors That Increase the Relative Risk for Breast Cancer in Women
Table 3.14: Age-specific Probabilities of Developing Invasive Female Breast Cancer
Table 4.1: Global Breast Cancer Incidence Rate as of 2008
Table 4.2: Female Breast Cancer Risk Factors
Table 4.3: Female Breast Cancer Risk Factors: Relative Risk Range 2.1-4.0
Table 4.4: Female Breast Cancer Risk Factors: Relative Risk Range >4.0
Table 4.5: Probability of U.S. Women for being diagnosed With Breast Cancer
Table 4.6: Reconstructive Breast Procedures in the U.S., 2009
Table 4.7: Physician Coding and Payment
Table 4.8: Medicare Inpatient Hospital Payment
Table 4.9: Hospital Outpatient Services
Table 4.10: NCI Dollars Spent by Mechanism, 2008-2009
Table 4.11: Percent Share of Total NCI Dollars, 2005-2009
Table 4.12: NCI and its Historical Funding Trends, 2005-2009
Table 4.13: Percent Growth by Mechanism, 2005-2009
Table 4.14: NCI Research Project Grants, 2008-2009
Table 4.15: National Cancer Institute Extramural vs. In-house Funding
Table 4.16: NCI's Research Career Awards, 2008-2009
Table 4.17: Research Dollars by Various Cancers, 2005-2009
Table 4.17: Cancer Centers by State (P30 Core Grants), 2009
Table 4.18: Grant and Contract Awards by State, 2009
Table 4.19: National Cancer Institute New Investments, 2011
Table 4.20: Breast Cancer Screening Programs in the E.U. Member States in 2007
Table 4.21: Number of New Cases and Rates of Breast Cancer in U.K., 2007
Table 4.22: Number of New Cases and Rates of Breast Cancer in U.K., 2007
Table 4.23: Women Opting for Three Types of Procedures in U.K.
Table 4.24: Tumor Characteristics and Prognostic Factors, by type of Tumor
Table 4.25: Types of Primary Breast Reconstruction in U.K.
Table 4.26: Symmetrization Surgery and its Timing
Table 4.27: Postoperative Complications
Table 4.28: Complication Rates by Type of Surgery
Table 4.29: Some Breast Cancer Research Programs in U.K. as of January 2011
Table 4.30: Rates of Mammograms, Both Breasts and One Breast of All Ages 1996 to 2007
Table 4.31: Annual Numbers for Both Breasts for ages 20-85+ years, 1987- 2007
Table 4.32: Annual Number of Ultrasound Diagnostic Services for Breast Cancer (20 to 85+), 1993-2007
Table 4.33: Annual Number of Fine-Needle Aspiration Services for Breast Cancer (20 to 85+), 1993-2007
Table 4.34: Annual Number of Core Biopsy Services for Breast Cancer (20 to 85+), 1993-2007
Table 4.35: Annual Number of Ductogram Services for Breast Cancer (20 to 85+), 1995-2007
Table 5.1: Top Mammography System Companies, 2011
Table 5.2: Biomarkers Used in Cancer Diagnosis
Table 5.3: MQSA Certified Facilities and Accredited Mammography Units in the U.S., 2000-2010
Table 5.4: Number of Hospitals in the U.S.
Table 5.5: MQSA National Statistics on Number of Mammography Facilities and Procedures, 2011
Table 5.6: Digital Mammography Market Penetration in the U.S.
Table 5.7: U.S. Digital Mammography Market Model
Table 5.8: Business Plan for Digital Mammography
Table 5.9: Reimbursement Rate for Mammography Procedures in the U.S.
Table 5.10: MRI Biopsy Reimbursement: Facility Billing, 2010
Table 5.11: MRI Biopsy Reimbursement: Physician Billing, 2010
Table 5.12: Ultrasound Biopsy Reimbursement: Facility Billing, 2010
Table 5.13: Ultrasound Biopsy Reimbursement: Physician Billing, 2010
Table 5.14: Breast-Specific Gamma Imaging Reimbursement: Hospital Outpatient Department (Medicare Billing), 2010
Table 5.16: Radiologist and/or Surgeon Global Billing, 2010
Table 5.17: Top Ten Imaging Systems Purchased, 2006-2009
Table 5.18: Medical Imaging Equipment Installations in China and India, 2000-2009
Table 5.19: Availability of Medical Imaging Equipment per Million Populations in China and India, 2009
Table 5.20: Affordability for Medical Imaging in Emerging Economies
Table 6.1: Agfa's Medical Imaging Products
Table 6.2: Amgen's Cancer Product Pipeline as of 2010
Table 6.3: Ardent's Product Portfolio
Table 6.4: AstraZeneca's Marketed Products in Oncology, 2009-2010
Table 6.5: AstraZeneca's Performance in Oncology, 2007-2009
Table 6.6: Bard's Breast Products
Table 6.7: Biosound Esaote's Ultrasound Systems
Table 6.8: Performance of Bristol's Oncology Products, 2007-2009
Table 6.9: Canon's Imaging Products
Table 6.10: Chison's Ultrasound Product Portfolio
Table 6.11: Selected Clarient's Cancer Tests
Table 6.12: Encapsule's Products
Table 6.13: Fujifilm's Product Portfolio
Table 6.14: Fukuda's Ultrasound Products
Table 6.15: GE Healthcare's Medical Imaging Equipment and Contrast Media
Table 6.16: Genentech's Oncology/Hematology Pipeline
Table 6.17: Hitachi's Medical Imaging Product Portfolio
Table 6.18: Lantheus' Contrast Agent Products
Table 6.19: Medis' Software for Various Medical Imaging Modalities
Table 6.20: Medison's Medical Imaging Products
Table 6.21: Features of PCR Eleva CosimaX image plate reader
Table 6.22: Eleva workspot
Table 6.23: Application and Pixel Matrix of Eleva
Table 6.24: Pfizer's Oncology Pipeline as of 2010
Table 6.25: Pfizer's Clinical Trial Programs in Breast Cancer as of 2010
Table 6.26: Roche's Cancer Drugs, 2010
Table 6.27: Roche's Regulatory Filings for Cancer Drugs in the First Half of 2010
Table 6.28: Sanofi's Performance in Cancer Drugs
Table 6.29: Planmed's Mammography Systems
Table 6.30: Shimadzu's Product Portfolio
Table App. 4.1: Hardware Specifications
Table App. 5.1: Bridge Survey at a Glance
Table App. 5.2: Types of Information Women with MBC Find Important
Table App. 6.1: Clinical Trials in Mammography as of December 2010
Table App. 8.1: New and Near-Term Technologies for Breast Cancer Detection
Table App. 10.1: The Major Medical Radioisotope Producing Reactors, 2010
Table App. 10.1: Potential Reactor-Based Projects for 99MO Production, 2010-2024
Table App. 10.2: Processing Capacity of Major Reactors, 2010
Table App. 10.3: Demand Scenarios for 99Mo, 2010-2025

- Abviva, Inc.
- Agendia B.V.
- Agfa Healthcare
- Amgen, Inc.
- Analogic Corporation
- Ardent Sound, Inc
- AstraZeneca
- Aurora Imaging Technology, Inc.
- Aurora . T Dedicated Breast MRI System
- C.R. Bard, Inc.
- Biosound Esaote, Inc
- Bristol-Myers Squibb
- Canon U.S.A., Inc
- Chison Medical Imaging, Co., Ltd
- Clarient, Inc.
- Dako
- deCODE Genetics
- Dilon Technologies, Inc.
- Dexela
- Dexela Digital Mammography Workstation
- Eli Lilly
- Encapsule Medical Devices, LLC.
- Fonar Corporation
- Fujifilm Medical Systems USA, Inc.
- Fukuda Denshi Co., Ltd.
- GE Healthcare
- Genentech, Inc.
- Hitachi Medical Corporation
- Hologic, Inc.
- Computed Tomography Laser Mammography (CTLM)
- Konica Minolta Medical Imaging USA, Inc.
- MacKay LifeSciences
- Lantheus Medical Imaging, Inc.
- Medis Medical Imaging Systems BV
- Medical Tactile, Inc
- Medison America, Inc.
- Medtronic Navigation and Imaging
- MeVis Medical Solutions AG
- Naviscan PET Systems, Inc.
- NeoMatrix LLC
- Novartis AG
- Philips Healthcare
- Pfizer, Inc.
- Roche Holdings, Ltd.
- Sanarus Technologies, LLC
- Sanofi-Aventis
- Sectra Medical Systems
- Planmed
- Scanis, Inc.
- Siemens Healthcare
- SenoRx, Inc.
- Shimadzu Medical Systems
- SonoCine, Inc.
- TechniScan Medical Systems
- Toshiba America Medical Systems, Inc.
- U-Systems, Inc.
- Varian Medical Systems
- VuCOMP, Inc.

Note: Product cover images may vary from those shown

ALSO AVAILABLE

  • Positron Emission Tomography (PET) Markets - Product Thumbnail Image

    Positron Emission Tomography (PET) Markets

    • Language: English
    • 225 Pages
    • Published: July 2011
    • Region: Global
    FROM
  • Nuclear Cardiology Markets - Product Thumbnail Image

    Nuclear Cardiology Markets

    • Language: English
    • 252 Pages
    • Published: May 2011
    • Region: Global
    FROM
  • Ultrasound Markets - Product Thumbnail Image

    Ultrasound Markets

    • Language: English
    • 248 Pages
    • Published: June 2011
    • Region: Global
    FROM
  • Picture Archiving and Communications Systems (PACS) - Product Thumbnail Image

    Picture Archiving and Communications Systems (PACS)

    • Language: English
    • 298 Pages
    • Published: September 2011
    • Region: Global
    FROM
  • Medical Imaging Bundle - Product Thumbnail Image

    Medical Imaging Bundle

    • Language: English
    • 1714 Pages
    • Published: July 2012
    • Region: Global
    FROM

RELATED PRODUCTS

Our Clients

Our clients' logos